Skip to main navigation Skip to search Skip to main content

Increased Suicide Risk in Patients with Hidradenitis Suppurativa

  • Linnea Thorlacius
  • , Arnon D. Cohen
  • , Gunnar H. Gislason
  • , Gregor B.E. Jemec
  • , Alexander Egeberg*
  • *Corresponding author for this work

Research output: Contribution to journalArticleResearchpeer-review

Abstract

Patients with skin disorders are considered at a higher risk of depression and anxiety than the background population. Patients with hidradenitis suppurativa (HS) may be particularly affected. We explored the association between HS and depression, anxiety, and completed suicides in the Danish national registries, expanding to include data on suicidal behavior, using both a cross-sectional and a cohort study design. Both designs included 7,732 patients with HS and a background population of 4,354,137. The cohort study revealed that HS patients had an increased risk of completed suicide after adjustment for confounding factors (11 per 7,732 vs. 2,904 per 4,354,137) (hazard ratio [95% confidence interval] = 2.42 [1.07−5.45]; P = 0.0334) and an increased risk of antidepressant drug use (1.30 [1.17−1.45]; P < 0.0001). In contrast to previous studies, the cross-sectional baseline data revealed nonsignificant association with depression (odds ratio [95% confidence interval] = 1.13; 0.87−1.47]; P = 0.36 and hospitalization due to depression (1.32 [0.94−1.85]; P = 0.1083). To the best of our knowledge, no previous studies have reported on the increased risk of completed suicide among HS patients. The increased risk of completed suicide is not solely explained by lifestyle and demographic differences and the results highlight the profound impact HS has on the lives of patients with this often devastating disease.

Original languageEnglish
Pages (from-to)52-57
Number of pages6
JournalJournal of Investigative Dermatology
Volume138
Issue number1
DOIs
Publication statusPublished - Jan 2018

Funding

Dr. Jemec is a consultant and investigator for AbbVie and Novartis, has received unrestricted grants from Leo Pharma, and sits on the Advisory Board of AbbVie, InflaRx, Novartis, Janssen Pharmaceuticals, MSD, and Pierre Fabre; and investigator for AbbVie, Novartis, Sanofi, and Regeneron. Dr. Gislason is supported by an unrestricted research scholarship from the Novo Nordisk Foundation. Dr. Cohen has received research grants from Novartis and has served as a consultant, advisor or speaker to AbbVie, Dexcel Pharma, Janssen, Novartis, Perrigo, Pfizer, and Rafa. Dr. Egeberg has received research funding from Pfizer and Eli Lilly, and honoraria as consultant and/or speaker from Pfizer, Eli Lilly, Novartis, Galderma, and Janssen Pharmaceuticals.

Fingerprint

Explore the research areas of 'Increased Suicide Risk in Patients with Hidradenitis Suppurativa'.

Cite this